Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crispr Therapeutics Ag
(NQ:
CRSP
)
47.85
-1.00 (-2.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crispr Therapeutics Ag
< Previous
1
2
...
21
22
23
24
25
26
27
28
Next >
CRISPR Therapeutics's Return On Capital Employed Insights
February 16, 2022
Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter.
Via
Benzinga
Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal
January 29, 2022
Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up...
Via
Talk Markets
Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years
January 25, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have...
Via
Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
January 14, 2022
A rebound from Monday's lows faded, with the key indexes all down for the week.
Via
Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
3 Deep Value Moonshots to Ride Out Powell’s Taper Tantrum
January 10, 2022
These three companies might seem like zombies compared to other investing opportunities, but they'll be robust during the Fed taper.
Via
InvestorPlace
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
January 10, 2022
The companies hope to cure diseases of the liver, muscle and central nervous system.
Via
Investor's Business Daily
7 Stock Bargains Worth a Look After the Most Recent Pullback
December 27, 2021
Value investors may choose to buy stocks that are out of favor and from among beaten up stock bargains in a variety of sectors.
Via
InvestorPlace
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.
Via
InvestorPlace
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
December 22, 2021
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.
Via
Talk Markets
10 Bargain Stocks to Buy After Falling 30% in 2021
December 20, 2021
If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill.
Via
InvestorPlace
Biotech Playbook 2021: No Help From Small Caps In Q4
December 14, 2021
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...
Via
Talk Markets
Adobe Earnings Strangle Trade
December 11, 2021
Adobe announces earnings this week, and we plan on using an options strategy called a
Via
Talk Markets
CRISPR Therapeutics Is One of Today’s Best Biotech Value Investments
December 09, 2021
Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
December 07, 2021
Upgrades For CarMax Inc (NYSE:
Via
Benzinga
Why CRISPR Therapeutics Stock Sank 12.5% in November
December 05, 2021
The gene-editing specialist's share price is now down roughly 54% in 2021.
Via
The Motley Fool
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
November 30, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ:
Via
Benzinga
Biotech Stocks are Due for a Rally
November 22, 2021
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.
Via
Talk Markets
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?
November 21, 2021
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.
Via
The Motley Fool
Better Buy: Vertex Pharmaceuticals vs. CRISPR
November 20, 2021
The companies are collaborating on a potential blockbuster.
Via
The Motley Fool
Looking for Growth in Small and Mid Cap Life Science Stocks
November 15, 2021
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.
Via
Talk Markets
Being First Is Not Enough For Crispr Therapeutics
November 15, 2021
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.
Via
InvestorPlace
Why CRISPR Therapeutics Stock Fell 18.4% in October
November 04, 2021
The gene-editing specialist's stock is now down roughly 37% year to date.
Via
The Motley Fool
Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics
November 04, 2021
Vertex plans to develop gene-editing therapies with Mammoth Biosciences.
Via
The Motley Fool
3 Things About CRISPR Therapeutics That Smart Investors Know
October 20, 2021
The company's value isn't reflected in typical performance metrics.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:
Via
Benzinga
2 Gene-Editing Stocks to Have on Your Radar Right Now
October 17, 2021
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
Via
The Motley Fool
2 Top Healthcare Stocks That Could Be Bought Out in 2022
October 16, 2021
These two novel-drug makers could be top takeover targets next year.
Via
The Motley Fool
Exposures
COVID-19
If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today
October 16, 2021
The returns haven't been half bad, to say the least.
Via
The Motley Fool
Crispr: A Fallen Angel In Gene Editing
October 16, 2021
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...
Via
Talk Markets
< Previous
1
2
...
21
22
23
24
25
26
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.